| Tufts Medicine

By kbarbin, 16 February, 2024

Daffodil Day

Lowell General Hospital Auxiliary "Daffodil Day"

Beginning February 15, 2024

Pre-order bunches or potted flowers:

$10 per bunch
$12 per mini-potted daffodil
$25 "Spreading Kindness" (gifted to a patient or support staff at the hospital)

Pick up on March 21st at:

ERA Key Realty Services
1 Chelmsford St
Chelmsford MA 01824
169 Merrimack St
Lowell, MA 01852

100% of proceeds support cancer patients. Order deadline is March 15th.

EpicCare Link is an online tool provided by Tufts Medicine that allows community physicians to connect with Tufts Medicine’s Epic electronic health record systems. Physicians can view important information about their patients' care, including hospitalizations, specialist referrals and real-time clinical data.

It is an easy-to-use, intuitive, web-based application that provides convenient access to patient data. It fully complies with state and federal regulations for releasing Protected Health Information (PHI).

EpicCare Link is an online tool for connecting physicians and their staff to Tufts Medicine resources and patient information in a secure manner.

Access EpicCare Link

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

All genders

18+

Recruiting now

Cancer Center

Learn more

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OPERA-01)

Breast cancer, Locally advanced and metastatic breast cancer

All genders

18+

Recruiting now

Cancer Center

Learn more

Keros PAH Study

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to
Investigate the Safety and Efficacy of KER-012 in Combination with
Background Therapy in Adult Participants with Pulmonary Arterial
Hypertension (TROPOS Study)

Pulmonary arterial hypertension (PAH)

All genders

18-100

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

MIRIs Innovative Food as Medicine Study for Food Insecure Pregnant Patients

For decades, it’s been known that poor nutrition during pregnancy has negative impacts on maternal and child outcomes both in the short and long term. Unfortunately, due to socioeconomic and food access issues, likely secondary to structural racism in populations of color, nutrition in pregnancy is also an issue of health equity.

Display title

MIRI's Innovative Food as Medicine Study for Food-Insecure Pregnant Patients